Israel Corp in the First Quarter: ICL Raises Guidance, but Cash Still Has to Reach the Parent

The first quarter improves Israel Corp's starting point for 2026, but it does not change the basic economics of the company. ICL opened the year strongly, raised adjusted EBITDA guidance to $1.5 billion to $1.7 billion, and distributed cash that already reached the parent layer. That is real support for a holding company that can service debt and distribute dividends as long as the core asset keeps working. Still, the quarter's bridge shows that most of the improvement at ICL came from price, mainly potash, while raw materials, currencies and freight absorbed a large part of the benefit. Prodalim received a public market value and generated an approximately $11 million capital gain, but Israel Corp did not sell shares and did not receive cash. The current read is therefore better than at the end of 2025, but still limited: value is becoming clearer, while accessible cash still depends almost entirely on ICL.

Israel Corp Is Still About Access to Value

Israel Corp looks like a global chemicals company in the consolidated statements, but for shareholders it is mainly a holding company above ICL. Profit, cash flow and risk still come mostly from the core asset. The additional holdings, mainly Prodalim, AKVA and NOAP, are no longer negligible, but they do not yet create an independent earnings or cash layer alongside ICL.

That is why the quarter matters now. At the end of 2025, the open questions were whether ICL could maintain EBITDA and dividends, whether the parent layer would keep enough financing room, and whether Prodalim would stop being mostly an option. The quarter answers only part of that: ICL is stronger, the parent is more liquid, and Prodalim has a market price. But only one of those answers has already become cash, the dividend from ICL.

The market signal also supports a cautious read, not a clean victory lap. Short interest declined to 1.05% of float after higher levels in January, but it remains above the 0.27% sector average. Some skepticism has eased, yet the market still wants proof that improvement inside ICL will continue moving upstairs rather than staying inside the core asset.

ICL Raised Guidance, but Price Did Most of the Work

ICL delivered a strong opening quarter: sales of $2.023 billion versus $1.767 billion in the prior-year quarter, operating income of $235 million, adjusted EBITDA of $412 million, and net income of $126 million attributable to its shareholders. Guidance also improved, with a new 2026 adjusted EBITDA range of $1.5 billion to $1.7 billion, up from $1.4 billion to $1.6 billion.

The operating bridge explains why the headline should not be read too quickly. In the adjusted operating income bridge, price contributed $159 million. Volume barely contributed to operating income, because positive effects in potash, specialty agriculture products and white phosphoric acid were offset by lower volumes in bromine-based industrial solutions. On the negative side, raw materials reduced operating income by $75 million, exchange rates by $21 million, and transportation plus other expenses by another $23 million combined. This is a good quarter, but it mainly proves potash pricing power rather than a broad improvement across the whole system.

Potash is the center of the improvement. Segment sales rose to $503 million from $405 million, EBITDA rose to $172 million from $118 million, and EBITDA margin increased to 34% from 29%. ICL's potash CIF price was $362 per tonne, up 21% year over year, and production rose to 1.177 million tonnes. By contrast, Phosphate Solutions sales rose to $679 million, but EBITDA fell to $131 million because of sulphur and raw materials. Growing Solutions sales rose to $551 million, but EBITDA increased only to $49 million.

The Parent Got Cash, Prodalim Did Not Replace ICL

At the parent layer, the quarter looks better. Liquid assets of the company and headquarters companies were about $748 million, versus financial liabilities of about $683 million. After forward and swap transactions that economically reduce liabilities by about $35 million, net financial assets were about $100 million, compared with about $73 million at the end of 2025 and about $21 million at the end of March 2025.

But the cash source is still very clear. In the separate parent cash flow statement, operating cash flow was $28 million, mainly supported by $25 million of dividends from investees. ICL distributed $60 million during the quarter, and the share of Israel Corp and its investees was about $26 million. After the balance-sheet date, ICL approved another $69 million dividend, with an expected approximately $30 million share for Israel Corp and its investees.

All-in cash flexibility after actual cash uses is reasonable, but not as broad as consolidated profit may imply. The parent paid $7 million of interest, did not repay solo-level debt principal during the quarter, and ended with a $5 million cash increase. It also approved a $13 million dividend to its own shareholders, paid after the balance-sheet date. Covenants are far away, with equity of $3.07 billion versus minimum requirements of $360 million to $500 million, and an adjusted solo equity-to-assets ratio of 101% versus requirements of 20% to 25%. The practical constraint is not covenant breach, but the need to keep rolling debt with an average duration of about 1.8 years while dividends from ICL keep arriving.

Prodalim adds a value layer, but not a solution. It raised about NIS 370 million at a valuation of about NIS 2.1 billion, and Israel Corp's holding was diluted to 24.45% of share capital, or 23.26% on a fully diluted basis. The approximately $11 million accounting gain matters, but Israel Corp did not sell shares and did not receive cash. The earnings contribution is still small as well: Prodalim's net income on a 100% basis was $1 million, and its contribution to net income attributable to Israel Corp's shareholders was still zero.

Inside ICL, the acquisition of 49.9% of Bartek Ingredients for about $90 million is a reminder that even high-quality growth needs capital before it can support parent distributions. ICL consolidated Bartek, recognized an approximately $49 million liability for the put option, and its net financial liabilities rose to $2.569 billion, partly because of $135 million of secured borrowings related to the acquisition. This does not cancel the strong quarter, but it sharpens why EBITDA is not immediately the same as free cash available at the parent.

What Will Decide 2026

2026 is becoming a proof year. On the positive side, ICL raised guidance and maintained expected potash sales volumes of 4.5 million to 4.7 million tonnes. If potash keeps holding, and if phosphate and growing solutions can pass through part of the raw-material inflation, ICL's dividend base can look more comfortable. On the negative side, the first quarter already showed that sulphur, currencies and freight can eat a large part of the price improvement.

For Israel Corp, the next checkpoints are dividends from ICL, debt rolling at the parent, and whether Prodalim starts contributing profit or cash rather than only value. The Dead Sea issue remains in the background: the detailed agreement reduced uncertainty around concession assets, but post-2030 economics still depend on legislation, tender terms and regulation. The Pond 4 proceedings and the appeal in the Haifa claim do not change the quarter, but they remind investors that part of ICL's risk is operational and regulatory, not only commodity prices.

The current conclusion is that Israel Corp looks better after the first quarter, but has not stopped being a concentrated holding company. The market should measure it through three numbers: adjusted EBITDA and dividends at ICL, net financial assets and debt payments at the parent, and earnings contribution or monetization outside ICL. If all three advance together, the discount becomes harder to justify. If only potash stays strong while Prodalim remains value on paper, the positive quarter will look more like relief than a deeper change.